Nebraska Medicine Hematology/Oncology

www.nebraskamed.com

 

Rivaroxaban Inferior to Warfarin in Prevention of Recurrent Thrombosis in Antiphospholipid Ab Syndrome & Andexanet and Idarucizumab Safe and Effective at Reversing Anticoagulant Effects of DOACs

213 views
March 9, 2020
Comments 0
Login to view comments. Click here to Login